{"id":8407,"date":"2024-10-21T13:41:38","date_gmt":"2024-10-21T05:41:38","guid":{"rendered":"https:\/\/flcube.com\/?p=8407"},"modified":"2024-10-21T13:41:42","modified_gmt":"2024-10-21T05:41:42","slug":"chinas-nhsa-concludes-pre-negotiation-talks-for-national-reimbursement-drug-list","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=8407","title":{"rendered":"China&#8217;s NHSA Concludes Pre-Negotiation Talks for National Reimbursement Drug List"},"content":{"rendered":"\n<p>According to the Economic Observer, an independent Chinese weekly newsletter, a series of discussions preceding the National Reimbursement Drug List (NRDL) price negotiation occurred from October 16 to 18. These pre-negotiation talks, which serve as one-on-one communications prior to the formal negotiation process, were divided into three groups this year. Personnel from the National Healthcare Security Administration (NHSA) participated, aiming to provide enterprises with expectations of price reductions and guide them accordingly.<\/p>\n\n\n\n<p>Following the National Day Holiday, the NHSA reportedly completed fund calculations and pharmaceutical economic calculations at Xiaotangshan town in Beijing municipality. Traditionally, two groups of experts perform consecutive calculations, each presenting a price to the NHSA. The administration then determines a negotiated price based on specific rules, known as the &#8220;envelope price.&#8221;<\/p>\n\n\n\n<p>A communication meeting convened by the NHSA last month, which addressed the varieties that have passed the formal review, raised concerns among manufacturers. The meeting indicated that the comprehensive evaluation rate for the NRDL negotiations in 2024 is less than 50%, suggesting a potentially stricter negotiation process this year.<\/p>\n\n\n\n<p>This year&#8217;s NRDL price negotiation process highlights the ongoing efforts to balance affordability with accessibility in China&#8217;s healthcare system, as the NHSA works to secure the best possible prices for medicines included in the national reimbursement list.- <a href=\"https:\/\/flcube.com\">Flcube.com<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>According to the Economic Observer, an independent Chinese weekly newsletter, a series of discussions preceding&#8230;<\/p>\n","protected":false},"author":1,"featured_media":8409,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[4],"tags":[67,75,74],"class_list":["post-8407","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-policy-regulatory","tag-nhsa-prev-smia","tag-price-negotiations","tag-rdl"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>China&#039;s NHSA Concludes Pre-Negotiation Talks for National Reimbursement Drug List - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"According to the Economic Observer, an independent Chinese weekly newsletter, a series of discussions preceding the National Reimbursement Drug List (NRDL) price negotiation occurred from October 16 to 18. These pre-negotiation talks, which serve as one-on-one communications prior to the formal negotiation process, were divided into three groups this year. Personnel from the National Healthcare Security Administration (NHSA) participated, aiming to provide enterprises with expectations of price reductions and guide them accordingly.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=8407\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"China&#039;s NHSA Concludes Pre-Negotiation Talks for National Reimbursement Drug List\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=8407\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2024-10-21T05:41:38+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-10-21T05:41:42+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/10\/0ae4795910072dd2ab57e7964826b7be-scaled.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1463\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=8407#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=8407\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"China&#8217;s NHSA Concludes Pre-Negotiation Talks for National Reimbursement Drug List\",\"datePublished\":\"2024-10-21T05:41:38+00:00\",\"dateModified\":\"2024-10-21T05:41:42+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=8407\"},\"wordCount\":222,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=8407#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/10\\\/0ae4795910072dd2ab57e7964826b7be-scaled.jpeg\",\"keywords\":[\"NHSA (prev. SMIA)\",\"Price negotiations\",\"RDL\"],\"articleSection\":[\"Policy \\\/ Regulatory\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=8407#respond\"]}],\"copyrightYear\":\"2024\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=8407\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=8407\",\"name\":\"China's NHSA Concludes Pre-Negotiation Talks for National Reimbursement Drug List - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=8407#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=8407#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/10\\\/0ae4795910072dd2ab57e7964826b7be-scaled.jpeg\",\"datePublished\":\"2024-10-21T05:41:38+00:00\",\"dateModified\":\"2024-10-21T05:41:42+00:00\",\"description\":\"According to the Economic Observer, an independent Chinese weekly newsletter, a series of discussions preceding the National Reimbursement Drug List (NRDL) price negotiation occurred from October 16 to 18. These pre-negotiation talks, which serve as one-on-one communications prior to the formal negotiation process, were divided into three groups this year. Personnel from the National Healthcare Security Administration (NHSA) participated, aiming to provide enterprises with expectations of price reductions and guide them accordingly.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=8407#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=8407\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=8407#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/10\\\/0ae4795910072dd2ab57e7964826b7be-scaled.jpeg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/10\\\/0ae4795910072dd2ab57e7964826b7be-scaled.jpeg\",\"width\":2560,\"height\":1463,\"caption\":\"China's NHSA Concludes Pre-Negotiation Talks for National Reimbursement Drug List\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=8407#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"China&#8217;s NHSA Concludes Pre-Negotiation Talks for National Reimbursement Drug List\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"China's NHSA Concludes Pre-Negotiation Talks for National Reimbursement Drug List - Insight, China&#039;s Pharmaceutical Industry","description":"According to the Economic Observer, an independent Chinese weekly newsletter, a series of discussions preceding the National Reimbursement Drug List (NRDL) price negotiation occurred from October 16 to 18. These pre-negotiation talks, which serve as one-on-one communications prior to the formal negotiation process, were divided into three groups this year. Personnel from the National Healthcare Security Administration (NHSA) participated, aiming to provide enterprises with expectations of price reductions and guide them accordingly.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=8407","og_locale":"en_US","og_type":"article","og_title":"China's NHSA Concludes Pre-Negotiation Talks for National Reimbursement Drug List","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=8407","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2024-10-21T05:41:38+00:00","article_modified_time":"2024-10-21T05:41:42+00:00","og_image":[{"width":2560,"height":1463,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/10\/0ae4795910072dd2ab57e7964826b7be-scaled.jpeg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=8407#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=8407"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"China&#8217;s NHSA Concludes Pre-Negotiation Talks for National Reimbursement Drug List","datePublished":"2024-10-21T05:41:38+00:00","dateModified":"2024-10-21T05:41:42+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=8407"},"wordCount":222,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=8407#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/10\/0ae4795910072dd2ab57e7964826b7be-scaled.jpeg","keywords":["NHSA (prev. SMIA)","Price negotiations","RDL"],"articleSection":["Policy \/ Regulatory"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=8407#respond"]}],"copyrightYear":"2024","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=8407","url":"https:\/\/flcube.com\/?p=8407","name":"China's NHSA Concludes Pre-Negotiation Talks for National Reimbursement Drug List - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=8407#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=8407#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/10\/0ae4795910072dd2ab57e7964826b7be-scaled.jpeg","datePublished":"2024-10-21T05:41:38+00:00","dateModified":"2024-10-21T05:41:42+00:00","description":"According to the Economic Observer, an independent Chinese weekly newsletter, a series of discussions preceding the National Reimbursement Drug List (NRDL) price negotiation occurred from October 16 to 18. These pre-negotiation talks, which serve as one-on-one communications prior to the formal negotiation process, were divided into three groups this year. Personnel from the National Healthcare Security Administration (NHSA) participated, aiming to provide enterprises with expectations of price reductions and guide them accordingly.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=8407#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=8407"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=8407#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/10\/0ae4795910072dd2ab57e7964826b7be-scaled.jpeg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/10\/0ae4795910072dd2ab57e7964826b7be-scaled.jpeg","width":2560,"height":1463,"caption":"China's NHSA Concludes Pre-Negotiation Talks for National Reimbursement Drug List"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=8407#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"China&#8217;s NHSA Concludes Pre-Negotiation Talks for National Reimbursement Drug List"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/10\/0ae4795910072dd2ab57e7964826b7be-scaled.jpeg","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/8407","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=8407"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/8407\/revisions"}],"predecessor-version":[{"id":8410,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/8407\/revisions\/8410"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/8409"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=8407"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=8407"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=8407"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}